RU2585228C2 - Модификация рекомбинантного аденовируса иммуногенными эпитопами белка circumsporozoite плазмодия - Google Patents

Модификация рекомбинантного аденовируса иммуногенными эпитопами белка circumsporozoite плазмодия Download PDF

Info

Publication number
RU2585228C2
RU2585228C2 RU2012110255/10A RU2012110255A RU2585228C2 RU 2585228 C2 RU2585228 C2 RU 2585228C2 RU 2012110255/10 A RU2012110255/10 A RU 2012110255/10A RU 2012110255 A RU2012110255 A RU 2012110255A RU 2585228 C2 RU2585228 C2 RU 2585228C2
Authority
RU
Russia
Prior art keywords
adenovirus
protein
seq
sequence
modified
Prior art date
Application number
RU2012110255/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2012110255A (ru
Inventor
Такаюки СИРАЦУТИ
Мория Цудзи
Original Assignee
Дзе Рокфеллер Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Рокфеллер Юниверсити filed Critical Дзе Рокфеллер Юниверсити
Publication of RU2012110255A publication Critical patent/RU2012110255A/ru
Application granted granted Critical
Publication of RU2585228C2 publication Critical patent/RU2585228C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2012110255/10A 2009-08-18 2010-08-18 Модификация рекомбинантного аденовируса иммуногенными эпитопами белка circumsporozoite плазмодия RU2585228C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2009/054212 2009-08-18
PCT/US2009/054212 WO2011022002A1 (en) 2009-08-18 2009-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
PCT/US2010/045952 WO2011022522A1 (en) 2009-08-18 2010-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes

Publications (2)

Publication Number Publication Date
RU2012110255A RU2012110255A (ru) 2013-09-27
RU2585228C2 true RU2585228C2 (ru) 2016-05-27

Family

ID=43607237

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012110255/10A RU2585228C2 (ru) 2009-08-18 2010-08-18 Модификация рекомбинантного аденовируса иммуногенными эпитопами белка circumsporozoite плазмодия

Country Status (16)

Country Link
US (1) US20170348405A1 (enExample)
EP (2) EP2467157A4 (enExample)
JP (2) JP5947719B2 (enExample)
KR (1) KR20120094469A (enExample)
CN (2) CN103025349B (enExample)
BR (1) BR112012003808A2 (enExample)
CA (1) CA2769415A1 (enExample)
IL (1) IL217709A (enExample)
MX (1) MX339830B (enExample)
NZ (1) NZ598703A (enExample)
PH (1) PH12012500164A1 (enExample)
RU (1) RU2585228C2 (enExample)
SG (2) SG10201404970PA (enExample)
UA (1) UA108081C2 (enExample)
WO (2) WO2011022002A1 (enExample)
ZA (1) ZA201201286B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154199A1 (en) 2010-10-18 2012-11-15 The Government Of The United States, As Represented By The Secretary Of The Army Soluble recombinant plasmodium falciparum circumsporozoite protein
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
AU2014275772B2 (en) * 2013-06-03 2020-01-02 Vlp Therapeutics, Inc. Malaria vaccine
JP6934862B2 (ja) * 2015-09-16 2021-09-15 アーティフィシャル セル テクノロジーズ インコーポレイテッド 抗マラリア組成物および方法
DK3405582T3 (da) * 2016-01-21 2020-11-02 Janssen Vaccines & Prevention Bv Forbedret adenovirusbaseret malaria-vaccine, der koder for og fremviser et malaria-antigen
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN107841513B (zh) * 2016-09-18 2023-04-14 中国科学院上海巴斯德研究所 基于M2e表位的广谱型流感疫苗
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN108192876A (zh) * 2017-12-07 2018-06-22 东莞市第八人民医院 一种人3型腺病毒衣壳蛋白同时展示ca16双中和抗原表位疫苗候选株的制备方法和应用
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
WO2020221451A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies binding to plasmodium circumsporozoite protein and uses thereof
CN110687289B (zh) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Fgl2蛋白作为疟疾感染标志物的应用
GB201915905D0 (en) * 2019-11-01 2019-12-18 Spybiotech Ltd Viruses with modified capsid proteins
JP2021178021A (ja) * 2020-05-14 2021-11-18 株式会社三洋物産 遊技機
US20240240203A1 (en) * 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
EP4404947A4 (en) * 2021-09-23 2025-12-10 Sagittarius Bio Inc Adenovirus and Methods of Using Adenovirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140474A1 (en) * 2006-10-26 2008-11-20 Johns Hopkins University Recombinant adenovirus vaccines
RU2356577C9 (ru) * 2002-10-23 2009-08-10 Глаксосмитклайн Байолоджикалс С.А. Способы вакцинации против малярии

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066623A (en) * 1993-11-23 2000-05-23 The United States Of America As Represented By The Secretary Of The Navy Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines
CA2453880A1 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
NZ539813A (en) * 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
US7611868B2 (en) * 2003-05-14 2009-11-03 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Recombinant modified adenovirus fiber protein
JP2005287309A (ja) * 2004-03-31 2005-10-20 Dnavec Research Inc 遺伝子導入を増強するための薬剤および方法
CN101072879B (zh) * 2004-10-13 2011-05-11 克鲁塞尔荷兰公司 改良的腺病毒载体及其应用
WO2007027860A2 (en) * 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2356577C9 (ru) * 2002-10-23 2009-08-10 Глаксосмитклайн Байолоджикалс С.А. Способы вакцинации против малярии
WO2008140474A1 (en) * 2006-10-26 2008-11-20 Johns Hopkins University Recombinant adenovirus vaccines

Also Published As

Publication number Publication date
JP2013502221A (ja) 2013-01-24
SG178476A1 (en) 2012-03-29
EP3412306A3 (en) 2019-01-02
KR20120094469A (ko) 2012-08-24
EP2467157A1 (en) 2012-06-27
EP3412306A2 (en) 2018-12-12
PH12012500164A1 (en) 2022-03-09
WO2011022002A1 (en) 2011-02-24
US20170348405A1 (en) 2017-12-07
CN105770880A (zh) 2016-07-20
CN103025349B (zh) 2016-05-18
AU2010286187A1 (en) 2012-02-16
WO2011022522A1 (en) 2011-02-24
HK1179508A1 (zh) 2013-10-04
SG10201404970PA (en) 2014-10-30
MX2012002131A (es) 2012-04-11
CA2769415A1 (en) 2011-02-24
JP2016146837A (ja) 2016-08-18
UA108081C2 (uk) 2015-03-25
IL217709A0 (en) 2012-03-29
NZ598703A (en) 2014-04-30
BR112012003808A2 (pt) 2016-11-16
CN103025349A (zh) 2013-04-03
JP5947719B2 (ja) 2016-07-06
RU2012110255A (ru) 2013-09-27
EP2467157A4 (en) 2014-01-22
MX339830B (es) 2016-06-13
JP6293181B2 (ja) 2018-03-14
ZA201201286B (en) 2013-05-29
IL217709A (en) 2016-05-31

Similar Documents

Publication Publication Date Title
RU2585228C2 (ru) Модификация рекомбинантного аденовируса иммуногенными эпитопами белка circumsporozoite плазмодия
JP2013502221A5 (enExample)
US9555089B2 (en) Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
WO2012023995A1 (en) Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
JP5222289B2 (ja) マラリア用ワクチン
JP6110347B2 (ja) 新規方法および組成物
US20100272786A1 (en) Vaccine
JP2009505680A (ja) アデノウイルスベクターに基づくマラリアワクチン
EP3368068B1 (en) Virus like particle with efficient epitope display
Shiratsuchi et al. A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII
Palma et al. Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice
Bruder et al. Molecular vaccines for malaria
AU2010286187B2 (en) Modification of recombinant adenovirus with immunogenic Plasmodium circumsporozoite protein epitopes
JP2011505796A (ja) ワクチン
HK1179508B (en) Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
JP7711050B2 (ja) アデノウイルスベクターおよびその使用
EA047117B1 (ru) Аденовирусные векторы и их применения
WO2011133870A2 (en) Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap)
Serotype Immunogenicity and Protection of

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190819